Sunday, January 6, 2019

Allergy to cure epilepsy nearly killed baby

Seven year old child was faced with severe reaction to a popular antiepileptic drug. His state of health has deteriorated so much that doctors have advised parents prepare for the worst.


 Allergy to cure epilepsy nearly killed baby  Stevens-Johnson syndrome


The five-year Englishman Ellis Stacey suffered an epileptic fit, after which the doctor prescribed him cure epilepsy Tegretol . which is used widely among children and adults. However, a Several days after the beginning of reception Tegretol Ellis felt very bad, and his body was covered with terrible bloody blisters, reminiscent of burn marks.


 Allergy to cure epilepsy nearly killed baby  Stevens-Johnson syndrome


The boy was faced with the most severe allergic reaction to Tegretol that case, according to experts, one case per million. Because of allergy skin on his face, trunk, arms and feet start peeling off. Doctors diagnosed him Stevens-Johnson syndrome   or malignant exudative erythema. This is a very severe form multiforme erythema at which bubbles appear on the mucous membrane of the mouth, throat, eyes, genitals and all over the body.


The boy's parents immediately We proposed to prepare for the worst, because even in prosperous countries with very high medicine Stevens-Johnson syndrome kills 40% of its victims. A Ellis's condition deteriorated dramatically from day to day. In addition, the boy suffered unbearable pain, so doctors have connected it to a drip morphine. This analgesic serious respiratory depression, and next to a small patient doctors on duty 24 hours a day.


Two weeks spent in the boy bed with tubes connected to it, for which he received the power, as independently of food intake is not out of the question. His eyes and lips are constantly lubricated to avoid scarring and soldering. It was only on the 15th day of the state the child began to improve, and as rapidly as it worsens, but a week later, he was discharged home. (READ MORE)



Industry News

Go back to the main page

No comments:

Post a Comment